Calamos Wealth Management LLC Boosts Stake in Bristol-Myers Squibb (NYSE:BMY)

Calamos Wealth Management LLC grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 2.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 11,123 shares of the biopharmaceutical company’s stock after buying an additional 270 shares during the quarter. Calamos Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $629,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Algert Global LLC bought a new position in Bristol-Myers Squibb in the second quarter worth approximately $328,000. AMF Tjanstepension AB lifted its holdings in shares of Bristol-Myers Squibb by 6.9% in the 3rd quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after buying an additional 39,419 shares during the period. Czech National Bank grew its position in shares of Bristol-Myers Squibb by 6.9% during the 3rd quarter. Czech National Bank now owns 413,002 shares of the biopharmaceutical company’s stock worth $21,369,000 after buying an additional 26,718 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Bristol-Myers Squibb by 61.3% during the third quarter. GAMMA Investing LLC now owns 27,386 shares of the biopharmaceutical company’s stock valued at $1,417,000 after buying an additional 10,410 shares during the period. Finally, SignalPoint Asset Management LLC bought a new stake in shares of Bristol-Myers Squibb in the third quarter valued at about $201,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Bristol-Myers Squibb Trading Down 1.3 %

Shares of Bristol-Myers Squibb stock opened at $59.15 on Wednesday. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.10. The firm’s 50 day simple moving average is $57.63 and its two-hundred day simple moving average is $53.47. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm has a market capitalization of $119.97 billion, a price-to-earnings ratio of -16.48, a PEG ratio of 2.10 and a beta of 0.45.

Bristol-Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date of this dividend was Friday, January 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 4.19%. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s payout ratio is currently -69.08%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their target price for the stock from $63.00 to $70.00 in a report on Monday, December 16th. UBS Group lifted their price objective on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, October 9th. Cantor Fitzgerald boosted their price objective on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wolfe Research started coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Finally, BMO Capital Markets upped their price objective on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $56.93.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.